Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,